AbbVie (NYSE:ABBV) Stock Price Down 1.3% – Here’s Why

AbbVie Inc. (NYSE:ABBV) traded down 1.3% during trading on Wednesday . The company traded as low as $213.75 and last traded at $214.72. 5,581,613 shares changed hands during mid-day trading, a decline of 24% from the average session volume of 7,351,497 shares. The stock had previously closed at $217.49.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Potential tax windfall — analyses say recent federal tax changes pushed corporate cash tax bills materially lower, which could improve AbbVie’s cash flow and net cash taxes versus prior expectations. US Corporate Taxes Drop $65 Billion After Trump’s $3.4 Trillion Tax Law
• Positive Sentiment: Allergan Aesthetics consumer push — AbbVie’s Allergan Aesthetics rolled out its CoolMonth promotion, a recurring revenue and demand driver in the aesthetics business (incremental, but recurring). Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth
• Positive Sentiment: Near-term buying interest — recent market coverage flagged a modest uptick in AbbVie shares amid broader market moves, suggesting some investor buying despite underperformance vs. the market. AbbVie Inc. stock rises Tuesday, still underperforms market
• Neutral Sentiment: Upcoming earnings catalyst — AbbVie will report Q1 2026 results on April 29; investors will focus on guidance, Imbruvica pricing/volume, and contributions from newer oncology drugs. AbbVie to Host First-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Industry read — a new PatentVest report highlights heavy investment in obesity (amylin) programs; broader shifts in pharma priorities and deal activity could indirectly affect AbbVie’s M&A and pipeline strategy. PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race
• Negative Sentiment: Litigation tied to Cerevel deal — a Bloomberg Law ruling forces Pfizer and Bain to litigate a suit by Cerevel investors over AbbVie’s deal, adding legal uncertainty and potential transaction risk/drag on the acquisition timeline. Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit
• Negative Sentiment: Oncology headwinds — analyst commentary flags pricing pressure on Imbruvica and a possible 2026 sales dip despite new oncology launches, which could weigh on top‑line growth expectations. Will AbbVie’s Oncology Drugs Aid Top Line in 2026?
• Negative Sentiment: Competitive pressure — recent large oncology M&A (e.g., Merck’s deal) strengthens rivals’ pipelines and could intensify competition in key oncology markets. Merck Just Made a Big Bet on a New Cancer Growth Engine

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ABBV shares. Piper Sandler increased their price objective on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Morgan Stanley boosted their target price on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and increased their price target for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research note on Tuesday, January 20th. Finally, BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Price Performance

The stock has a market cap of $379.66 billion, a P/E ratio of 90.98, a PEG ratio of 0.74 and a beta of 0.34. The stock has a 50-day simple moving average of $222.00 and a 200-day simple moving average of $224.65.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the prior year, the business earned $2.16 earnings per share. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Insiders Place Their Bets

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.25% of the company’s stock.

Institutional Trading of AbbVie

Hedge funds have recently made changes to their positions in the company. J. Derek Lewis & Associates Inc. bought a new stake in AbbVie during the 4th quarter worth approximately $4,173,000. Purpose Unlimited Inc. bought a new position in shares of AbbVie during the fourth quarter valued at $172,000. Stance Capital LLC lifted its holdings in shares of AbbVie by 1.4% during the fourth quarter. Stance Capital LLC now owns 6,240 shares of the company’s stock worth $1,426,000 after purchasing an additional 86 shares during the period. Cornerstone Planning LLC acquired a new position in shares of AbbVie during the fourth quarter worth $3,421,000. Finally, Rockefeller Capital Management L.P. grew its stake in shares of AbbVie by 10.1% in the fourth quarter. Rockefeller Capital Management L.P. now owns 883,644 shares of the company’s stock worth $201,904,000 after purchasing an additional 81,375 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.